

Tessengerlo Group completes sale of pharmaceutical ingredients activities

Released on 11/12/12

Tessengerlo Group (NYSE Euronext: TESB) announced today that it has completed the sale of its pharmaceutical ingredients activities in Calaire (France) and Farchemia (Italy) to International Chemical Investors Group (ICIG), a private industrial holding company.

On October 9 2012, the group announced its intention to divest the pharmaceutical ingredients activities Calaire and Farchemia. Information and consultation procedures were completed early November. After clearance by the merger control authorities , the sale was completed on December 5 2012.

This divestment is in line with Tessenderlo Group`s strengthened focus on specialty products and services in the areas of food, agriculture, water management and valorizing bio-residuals.

Calaire and Farchemia employ some 360 employees.

Tessengerlo Group is a worldwide specialty company, focused on food, agriculture, water management and on valorizing bio-residuals. The group employs about 7,500 people and is a leader in most of its markets, with a consolidated revenue of 2.1 billion EUR in 2011. Tessenderlo Chemie NV is listed on NYSE Eurolist by Euronext Brussels and is part of Next 150 and BEL Mid indices. Financial News wires: Bloomberg: TESB BB - Reuters: TesBt. BR - Datastream: B:Tes

International Chemical Investors Group (ICIG) is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. Since inception in 2004, ICIG has acquired 17 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed. ICIG companies currently employ more than 3,300 people and operate 17 manufacturing facilities in Europe and the United States with total sales of approximately €700 million.

Source [Yahoo Finance](#)